Browsing: GLP1

As adults take a more serious look at GLP-1 weight-management care in 2026, this Pallas Health review examines its doctor-led telehealth model, compounded semaglutide and tirzepatide options, FDA-approved brand-name pathways, current pricing, and what consumers should compare before beginning an eligibility evaluation

(NewsNation) — Luxury vacations are getting an upgrade with a healthy dose of GLP-1s

Some Medicare patients can now receive GLP-1 medication at low cost. The U.S. Centers for Medicare and Medicaid Services started the GLP-1 Bridge Program July 1st to help patients pay for certain weight-loss medicines. Beneficiaries have to meet certain requirements, including a specified body mass index

About 1 in 5 American adults has already tried a GLP-1 medication, and as costs come down, that number is expected to keep climbing. Drugs like Ozempic and Wegovy are topping health trends in 2026, and their reach is expanding beyond weight loss into treatments for heart disease, kidney disease, arthritis and even addiction

As demand for flexible GLP-1 telehealth options continues in 2026, this CoreAge Rx review examines the brand-stated compounded semaglutide and tirzepatide programs, online licensed-provider evaluation, cash-pay pricing structure, pharmacy fulfillment, and the key details adults should compare before deciding whether the program fits their weight-management goals

According to a KFF Health Tracking Poll, roughly one in eight US adults has now taken a GLP-* medication (KFF Health Poll, ****, as cited by ReturnPro, August *, ****), a scale ReturnPro calls “one of the fastest growing health trends influencing apparel retail.” Separately, market research firm Circana found that ** per cent of…

Victoria Schmidt was scrolling through TikTok last July when the advertisement first appeared: a video of a woman promoting patches purporting to contain GLP-1 medication

Popular anti-obesity drugs such as Wegovy, which belong to the glucagon-like peptide-1 (GLP-1) class, have been thought to work by suppressing hunger-inducing neurons. New findings now overturn that hypothesis, suggesting instead that these drugs activate the very neurons that promote hunger. 

People who want to lose weight with a GLP-1 drug can choose from an ever-growing number of telehealth companies offering the medications online

Regenics has launched a new physician-led GLP-1 membership program that combines ongoing clinical oversight with lower medication pricing, offering semaglutide and tirzepatide alongside pharmaceutical-grade peptide and hormone optimization therapies, telemedicine access across the U.S., and complimentary medication delivery for eligible patients